Legal
disclosures.

No offer or solicitation

This website provides general information about Colibri Capital LLC (“Colibri”) and its areas of interest. Neither this website nor any statement, company reference, link, or communication through it constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation to acquire any security, fund interest, or other investment. No investment may be subscribed for or purchased through this website.

Any offering, if made, would be made only through definitive confidential offering materials, subscription documents, and governing agreements supplied to eligible prospective investors in accordance with applicable law. Those documents, including their risk factors and disclosures, govern any investment and supersede website summaries to the extent of any inconsistency. No opportunity is promised to be available, and an inquiry does not reserve an allocation or bind Colibri to accept an investor.

Accredited investors only

Any investment opportunity that Colibri may make available is intended solely for persons or entities that qualify as “accredited investors” under Rule 501(a) of Regulation D under the Securities Act of 1933, as amended, and satisfy all other applicable legal and offering-specific requirements. Additional qualifications, including qualified purchaser or qualified client status, may apply depending on the vehicle and arrangement.

Access to this website, a conversation with Colibri, or a self-certification does not establish eligibility or acceptance. Appropriate information and documentation may be required to assess or verify status under the applicable offering framework. Accredited status does not establish that an investment is suitable or safe. Prospective investors must be able to evaluate the merits and risks and bear the economic risk of a complete loss.

For background, see the SEC’s explanation of accredited investor assessment (opens in a new tab).

Offering restrictions & regulatory status

No offering exemption, investment adviser registration, broker-dealer registration, or regulatory approval should be inferred from this website. The applicable legal framework and relevant parties’ status must be established from current offering materials and appropriate regulatory records. No securities regulator has endorsed Colibri, a referenced company, an investment strategy, or the merits of any potential investment.

Information is not directed to any person or jurisdiction where its distribution or use would violate law. Offers and sales, if any, remain subject to applicable federal, state, and non-U.S. requirements and any relationship, solicitation, verification, or other restrictions under the exemption used. The presence of these disclosures does not itself create an exemption or authorize a solicitation. The SEC explains these distinctions in its general solicitation guidance (opens in a new tab).

Investment risk & illiquidity

Private investments are speculative and may result in the loss of the entire amount invested. Securities may be unregistered, subject to significant transfer restrictions, and lack any public or secondary market. Investors may need to hold an investment indefinitely; withdrawals, redemptions, distributions, and an exit may be unavailable. Financial reporting and public information may be more limited than for publicly traded securities.

Business failure, adverse economic conditions, financing constraints, dilution, valuation uncertainty, and legal or regulatory changes can impair value. A fund or special purpose vehicle may hold a single investment or a small number of investments, magnifying company-specific and sector-specific risk. Estimated values may differ materially from realizable proceeds. No target return, capital preservation, liquidity event, or distribution is assured.

These are selected risks, not a complete list. Review the applicable offering documents and the SEC’s private placement investor bulletin (opens in a new tab).

Fees, expenses & conflicts of interest

Depending on the definitive terms, a vehicle may bear management fees, performance allocations or carried interest, organizational expenses, professional fees, and other costs. These reduce investor returns and may be incurred even when an investment loses value. Review the actual fee arrangements, expense allocations, distribution provisions, and any capital-call or default obligations before committing.

Potential conflicts may involve the allocation of opportunities among vehicles or accounts; investments by management or affiliates; valuation and exit decisions; affiliated services; or different economic terms for different investors. Compensation arrangements may create incentives that differ from an investor’s interests. The applicable documents must be reviewed for the specific conflicts, procedures, rights, and limitations of each arrangement. Website descriptions do not promise that a particular term, fee, or conflict-management process applies.

Biotechnology & CAD Therapeutics

Proposed investment — not closed. The proposed investment in CAD Therapeutics, Inc. has not closed and is not a completed portfolio holding. There is no assurance that the investment will be completed.

Biotechnology investments face substantial scientific, clinical, regulatory, intellectual property, manufacturing, reimbursement, commercialization, and financing risks. Studies may fail, be delayed, require additional work, or reveal unexpected safety issues. Regulatory authorization, market acceptance, and commercial success may never occur.

References to CAD Therapeutics, Inc., post-traumatic stress disorder (PTSD), and vasomotor symptoms (VMS, including hot flashes) describe an investigational area of focus. The referenced product candidate is investigational and is not FDA-approved for these uses; its safety and efficacy for these uses have not been established. A reference to Phase III describes a development stage and does not mean FDA approval, proven efficacy, endorsement, or a guarantee of future approval. It should not be interpreted as confirmation that a particular trial is currently enrolling or complete.

This website does not provide medical advice, recommend treatment, or recruit clinical trial participants. Development status can change; consult current company disclosures and relevant regulatory information. The FDA describes the clinical research stages in its drug development overview (opens in a new tab).

Other sector-specific risks

Technology, media, and telecommunications investments may be affected by rapid obsolescence, cybersecurity incidents, platform dependence, competition, and changes in intellectual property or content rules. Financial technology investments may face payments, lending, consumer protection, data privacy, counterparty, and licensing risks. Infrastructure investments may face construction delays, cost overruns, permitting restrictions, environmental liabilities, physical disruption, and changing demand or interest rates. The sectors shown on this website describe areas of interest and do not promise diversification or investments in each area.

Performance & forward-looking statements

Past performance, if referenced, does not predict or guarantee future results. A management biography, prior employer, business relationship, or referenced company is not a track record of a Colibri vehicle. Company logos and selected examples do not represent all investments, establish ownership or endorsement, or imply that a transaction has closed or generated a return.

Statements about objectives, expectations, plans, prospects, future developments, or potential outcomes are forward-looking and subject to assumptions, uncertainties, and events beyond Colibri’s control. Actual outcomes may differ materially. No forecast, projection, or expression of optimism should be relied on as a promise. Information speaks as of its stated date, if any, and may change; updates are not assured except as required by applicable law.

Independent advice & investor diligence

Website content is not individualized investment, legal, tax, accounting, or medical advice. It does not consider a visitor’s objectives, finances, risk tolerance, or circumstances. Consult independent advisers and conduct your own diligence before making any decision. Tax treatment depends on individual circumstances and applicable law and may change.

Viewing the website or sending an inquiry does not by itself create an advisory, fiduciary, attorney-client, or other professional relationship. Any such relationship and its scope depend on applicable law and the relevant agreement. An investment in a vehicle is distinct from an investment directly in its manager or an underlying company; rights and obligations are defined by the governing documents.

Information, third-party links & intellectual property

Information may be based on company materials or other sources and may be incomplete, outdated, or subject to revision. Colibri does not warrant that website information is comprehensive, error-free, or suitable for a particular purpose. To the extent permitted by applicable law, the website is provided on an “as is” and “as available” basis, without warranties of uninterrupted or secure access.

External websites operate under their own terms and privacy practices. Links are provided for convenience or reference and do not imply an endorsement, a partnership, or responsibility for third-party content. Company names and trademarks belong to their respective owners. No license to use Colibri branding or third-party marks is granted by access to this website.

Communications & sensitive information

Email links on this site open your email service. If you contact Colibri, information you choose to include may be used to respond and consider your inquiry. Ordinary email should not be treated as a secure investor portal. Do not email passwords, Social Security numbers, identity documents, account credentials, or accreditation documentation through a general inquiry. Any required sensitive documents should be requested through an appropriate separate process.

Do not submit investment funds or wire instructions through this website. Verify any transaction instructions independently using a trusted contact method. Third-party websites and your email provider may collect or process information under their own policies. This communications notice is not a substitute for any privacy notice applicable to a future investor relationship.

Preservation of rights & contact

Nothing on this website or in these disclosures excludes obligations, limits liability, or waives rights or remedies that cannot lawfully be excluded, limited, or waived, including under applicable securities laws. These disclosures supplement general website information; they do not replace offering documents, required regulatory disclosures, or investor-specific notices.

For questions about this website or these disclosures, contact caleb@colibricapitalgp.com.